Compass Therapeutics, Inc. cotiza a 0.94 USD y tiene una capitalización bursátil de $169M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular e…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.13 | $-0.10 | $-0.09 |
| Estimado | $-0.13 | $-0.11 | $-0.10 | $-0.09 |
| Sorpresa | — | -18.2% | +0.0% | +0.0% |
| Métrica | CMPX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -33.8% | -40.4% | +6.6% |
| ROA | -30.3% | -32.0% | +1.7% |
| Current Ratio | 15.02 | 2.84 | +12.18 |
| Debt / Equity | — | 0.28 | — |